Consensus and Controversy in Pharmaceutical Statistics
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Drug development is a highly regulated business. Statistics plays an important part in measuring and reporting the efficacy and tolerability of pharmaceuticals and this is reflected in American, European, Japanese and international guidelines of some considerable detail which cover the way in which clinical trials are to be planned, run and analysed. The dominant framework for analysis is frequentist but Bayesian approaches are becoming more popular. Some controversial issues in drug development are considered in the light of the International Conference on Harmonisation's 1999 international statistical guidelines to see whether any Bayes-requentist consensus is possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can Quantum-Mechanical Description of Physical Reality Be Considered Complete?
Einstein, A., Podolsky, B., & Rosen, N. (1935) · Physical Review · doi:10.1103/physrev.47.777 · Cited by 16,654
Schuirmann, D. J. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01068419 · Cited by 2,696
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
The Two-Period Change-Over Design and Its Use in Clinical Trials
Grizzle, J. E. (1965) · Biometrics · doi:10.2307/2528104 · Cited by 784
Testing a Point Null Hypothesis: The Irreconcilability of P Values and Evidence
Berger, J. O., & Sellke, T. (1987) · Journal of the American Statistical Association · doi:10.2307/2289131 · Cited by 548
Testing for baseline balance in clinical trials
Senn, S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131703 · Cited by 503
Self-citationA comment on replication,P‐values and evidence
Goodman, S. N. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110705 · Cited by 309
Cited by
The method of minimization for allocation to clinical trials
Scott, N. W., McPherson, G. C., Ramsay, C. R., & Campbell, M. K. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00242-8 · Cited by 651
Multiple-bias modelling for analysis of observational data
Greenland, S. (2005) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1111/j.1467-985x.2004.00349.x · Cited by 497
ANOVA for unbalanced data: Use Type II instead of Type III sums of squares
Langsrud, Ø. (2003) · Statistics and Computing · doi:10.1023/a:1023260610025 · Cited by 469
Tsiatis, A. A., Davidian, M., Zhang, M., & Lu, X. (2008) · Statistics in Medicine · doi:10.1002/sim.3113 · Cited by 349
Bayesian statistics in medicine: a 25 year review
Ashby, D. (2006) · Statistics in Medicine · doi:10.1002/sim.2672 · Cited by 238
“In contrast to earlier read papers on clinical trials, one focusing on trials in the pharmaceutical industry addressed head on the Bayesian-frequentist debate and the extent to which Bayesian methods were or were not making inroads [270].”
Metadata
- Authors
- Senn, S.
- Venue
- Journal of the Royal Statistical Society: Series D (The Statistician)
- Publisher
- Wiley
- Published
- 2000-07
- Volume
- 49
- Issue
- 2
- Pages
- 135-176
- ISSN
- 0039-0526 (ISSN-L)
- 1467-9884
- OpenAlex
- W2114210536
- Cited by
- 77
- References
- 8
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consensus and Controversy in Pharmaceutical Statistics. https://app.cochat.ai/papers/10.1111/1467-9884.00227
- The paper
- Senn, S. (2000). Consensus and Controversy in Pharmaceutical Statistics. Journal of the Royal Statistical Society: Series D (The Statistician). https://doi.org/10.1111/1467-9884.00227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.